RxDoctor Payments Data

Lindy Rachal, MD

Gastroenterology · Kerrville, TXNPI 1275533150

Payments from drug & device makers

$4,853in general payments, 2019–2025

Across 321 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$709
  • Johnson & Johnson$470
  • Takeda Pharmaceuticals U.S.A., Inc.$252
  • Gilead$211
  • Madrigal Pharmaceuticals$153
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,846100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,853 in reported general payments places this provider in the 55th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$214,495
Medicare patients
837
Services billed
1,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$369,608
Humira(Cf) PenAdalimumab12$132,110
XifaxanRifaximin36$107,990
LinzessLinaclotide94$69,931
CreonLipase/Protease/Amylase44$23,795
ZenpepLipase/Protease/Amylase18$20,038
Ursodiol70$14,647
VoqueznaVonoprazan Fumarate17$12,605
TrulancePlecanatide15$12,326
Pantoprazole Sodium791$9,905
Mesalamine ErMesalamine20$8,662
SutabSod Sulf/Pot Chloride/Mag Sulf48$7,657
Dexlansoprazole DrDexlansoprazole14$6,057
CholestyramineCholestyramine (With Sugar)77$5,173
Budesonide DrBudesonide72$4,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$470$369,60815 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$709$120,31651 claims
AbbVieLinzess, Creon$1,594$93,726138 claims
Aimmune Therapeutics, Inc.Zenpep$96$20,03818 claims
Phathom Pharmaceuticals, Inc.Voquezna$38$12,60517 claims
Braintree Laboratories, Inc.Sutab$67$7,65748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Kerrville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →